FCA
ACAD icon

FinTrust Capital Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

FinTrust Capital Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-50
Closed -$2K – 1065
2020
Q3 		$2K Buy
+50
New +$2.16K ﹤0.01% 1050

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

FinTrust Capital Advisors's ACAD Position: Q4 2020 in Review

FinTrust Capital Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q4 2020, closing a stake of 50 shares — an estimated $2K sold.

FinTrust Capital Advisors first reported a position in ACAD in Q3 2020 and held it in 1 quarter. The position peaked at $2K in Q3 2020. 308 funds tracked by Wall St. Rank hold ACAD as of Q4 2020.

  • FinTrust Capital Advisors reported no remaining Acadia Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • FinTrust Capital Advisors sold 50 Acadia Pharmaceuticals shares in Q4 2020, an estimated $2K.
  • FinTrust Capital Advisors first reported a position in Acadia Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • FinTrust Capital Advisors's Acadia Pharmaceuticals position peaked at $2K in Q3 2020.
  • 308 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2020.

Based on FinTrust Capital Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.